Eli Lilly and Co (LLY) Releases Earnings Results, Misses Expectations By $-0.02 EPS

Eli Lilly and Co (LLY) reported quarterly earnings results on Tuesday, Apr-26-2016. The company reported $0.83 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $0.85. The company posted revenue of $4865.10 million in the period, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Co opened for trading at $77.1 and hit $77.94 on the upside on Friday, eventually ending the session at $77.83, with a gain of 0.59% or 0.46 points. The heightened volatility saw the trading volume jump to 26,97,164 shares. Company has a market cap of $86,087 M.

In a different news, on Feb 8, 2016, Stephen F Fry (SVP, HR & Diversity) sold 15,230 shares at $78.87 per share price. According to the SEC, on Feb 3, 2016, Jackson P Tai (director) purchased 3,170 shares at $78.62 per share price. On Feb 3, 2016, David A Ricks (SVP and Pres, Lilly Bio-Meds) sold 5,733 shares at $77.54 per share price, according to the Form-4 filing with the securities and exchange commission.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Eli Lilly and Co

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.